Daniel O'Day (AP Images)

Amid remde­sivir craze Gilead finds time for an­oth­er on­col­o­gy pact — loop­ing in all things NK cells

Gilead’s $4.9 bil­lion buy­out of Forty Sev­en, an­nounced in ear­ly March, land­ed in a dif­fer­ent era be­fore the pan­dem­ic con­sumed bio­phar­ma news. But even amid all the buzz around its po­ten­tial Covid-19 treat­ment remde­sivir, CEO Daniel O’Day is still mak­ing clear that on­col­o­gy is where he wants to take the com­pa­ny.

His lat­est deal is a re­search col­lab­o­ra­tion in­volv­ing a low-pro­file play­er head­quar­tered in Mel­bourne — so stealthy that the up­front pay­ment and to­tal val­ue are all still un­der wraps. What Gilead did re­veal, how­ev­er, is an in­ter­est in oNKo-in­nate’s ex­per­tise in nat­ur­al killer cells as a new fron­tier of im­muno-on­col­o­gy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.